VEGFA and hepatocellular carcinoma: This characteristic renders vascular-targeting approaches, namely, tyrosine kinase inhibition, appealing for the treatment of HCC; such agents include anti-vascular endothelial growth factor receptor (anti-VEGFR) and VEGF inhibitors (20, 26).